The US Food and Drug Administration (FDA) has approved lecanemab, the second-ever treatment for Alzheimer’s disease intended to tackle the root of the condition and slow cognitive decline. Researchers welcome the decision, but the excitement is clouded by patient deaths and reports that the FDA acted improperly when approving the first such drug last year.
By slowing progression of the disease when taken in the early stages of Alzheimer’s, lecanemab will allow individuals to have “more time to participate in daily life and live independently”, says Joanne Pike, president and chief executive of the Alzheimer’s Association in Washington DC, in a statement.
Learn More: https://www.nature.com/articles/d41586-023-00030-3
